FDA Names 4 Permanent Leaders, Installing Drug, Vaccine, Tobacco Directors

For healthcare leaders, regulators, and health IT teams, FDA leadership changes are not just Washington personnel news—they determine how quickly new drugs reach market, how vaccine policy evolves, and how clearly safety signals are communicated. The permanent appointment of Dr. Michael Davis and Karim Mikhail to key center roles reduces uncertainty after months of high-profile departures, but it also cements a Trump administration policy direction that will shape clinical evidence standards, patient safety, and public health decision-making.

On September 8, 2026, the Department of Health and Human Services announced that the Trump administration had filled four senior positions at the Food and Drug Administration, converting several acting leaders into permanent appointees and giving the agency a degree of stability after months of controversy and high-profile departures earlier in the year. According to AP reporting carried by both WHEC and the Orlando Sentinel, the announcement names permanent directors for three of the FDA's six centers: drugs, vaccines and biologics, and tobacco products. All three areas have experienced major policy shifts under the Trump administration and have drawn scrutiny from consumer groups, physicians, and congressional Democrats. The fourth senior role was not fully detailed in available wire reporting, but the overall package signals an attempt to settle leadership at an agency whose regulatory decisions affect nearly every dimension of American healthcare, from prescription drugs and vaccines to nicotine and tobacco products.

“

Michael Davis as permanent director of the Center for Drug Evaluation and Research, the FDA's largest center and the body responsible for the safety and effectiveness of prescription and over-the-counter drugs.

The most consequential appointment is Dr. Michael Davis as permanent director of the Center for Drug Evaluation and Research, the FDA's largest center and the body responsible for the safety and effectiveness of prescription and over-the-counter drugs. Davis had been serving in an acting role since the departure of Dr. Tracy Beth Hoeg, who said she was fired from the job in May. Hoeg's brief tenure was notably focused on scrutinizing antidepressants, COVID shots, and other drugs used in children, adding political and scientific tension to the role. Davis brings a background that is both traditional and unconventional for the post: he previously led within the FDA's psychiatric drug division, briefly left government to work at a nonprofit pursuing psychedelic drug development, and returned to the FDA as a deputy director last year. That combination places him at the center of one of the administration's stated regulatory priorities. Both President Donald Trump and Health Secretary Robert F. Kennedy have emphasized the need to speed up reviews of psychedelics, and Davis will now oversee a series of upcoming psychedelic drugs being studied for psychiatric conditions, including psilocybin, MDMA, and LSD.

The administration also named Karim Mikhail to lead the FDA's vaccines and biologics center on a permanent basis. Mikhail is described as a pharmacist and longtime pharmaceutical executive. The vaccines center occupies an especially sensitive policy position after years of intense public debate over COVID-19 vaccines, pediatric immunization schedules, and vaccine safety surveillance. Installing a permanent director with pharmaceutical industry experience may reduce operational uncertainty inside the agency, but it will also likely intensify scrutiny from vaccine policy advocates and lawmakers who closely track the center's advisory processes and safety communications. The permanent tobacco products director was also included in the announcement, although the wire report did not detail the individual's background, leaving a gap in public understanding of how nicotine regulation may shift next.